News

Article

AJMC® in the Press, April 5, 2024

Author(s):

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article in Bloomberg Law referenced a study published in the November 2023 issue of The American Journal of Managed Care®. The study, “Medicare Advantage in Rural Areas: Implications for Hospital Sustainability,” found that the increased penetration of Medicare Advantage from 2008 to 2019 was associated with greater hospital sustainability.

Related Videos
1 expert is featured in this series.
5 experts are featured in this series
Keith Ferdinand, MD, professor of medicine, Gerald S. Berenson chair in preventative cardiology, Tulane University School of Medicine
Related Content
FDA website | Image credit: Postmodern Studio – stock.adobe.com
December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Hayden E. Klein
The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.
Managed Care Cast
December 19th 2024

Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma

Giuliana Grossi
Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
FDA Approved
December 20th 2024

FDA Approves Encorafenib With Cetuximab and mFOLFOX6 for Metastatic CRC

Julia Bonavitacola
Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Dr Yehuda Handelsman
December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

Brooke McCormick
In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.
FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com
December 20th 2024

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

Cameron Santoro
The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo